Edition:
India

People: Pacira Biosciences Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

43.33USD
24 May 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$43.33
Open
$43.62
Day's High
$43.98
Day's Low
$43.26
Volume
97,318
Avg. Vol
183,750
52-wk High
$54.92
52-wk Low
$30.00

Pace, Gary 

Dr. Gary W. Pace, Ph.D., is Director of the Company. Dr. Pace has served as a director since June 2008. He was director to QRxPharma Ltd. (ASX: QRX) from 2001 to 2014. Dr. Pace has been a director of ResMed (NYSE: RMD) since 1994 and Transition Therapeutics Inc. (CDNX: TTH) since 2002. He previously served as a member of the board of directors at Celsion Corporation (NASDAQ: CLSN) from 2002 to 2010 and Peplin Inc. (ASX: PLI) from 2004 to 2009. He has more than 40 years of experience in the development and commercialization of advanced technologies, spanning biotechnology, pharmaceuticals, medical devices, and food industries. Dr. Pace was awarded a Centenary Medal by the Australian Government in 2003 "for service to Australian society in research and development" and was recognized as the 2011 Director of the Year (corporate governance) by the Corporate Directors Forum. Dr. Pace holds a B.Sc. with honors from the University of New South Wales and a Ph.D. from Massachusetts Institute of Technology.

Basic Compensation

Total Annual Compensation, USD 56,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 115,829
Fiscal Year Total, USD 171,829

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Stack

4,718,920

Charles Reinhart

1,318,940

Robert Weiland

1,924,580

Kristen Williams

1,527,720

Richard Scranton

1,686,600

Mark Froimson

197,923
As Of  31 Dec 2017